FINWIRES · TerminalLIVE
FINWIRES

Edgewise Therapeutics Faces Near-Term Upside From Cytokinetics' Upcoming Readout, RBC Says

By

Edgewise Therapeutics (EWTX) faces near-term upside opportunity with Cytokinetics' (CYTK) upcoming readout from its Acacia trial, RBC Capital Markets said in a note Friday.

The brokerage said that regardless of Cytokinetics' trial data, there may be positive readthroughs for Edgewise's EDG-7500 candidate, driving about 10% upside.

A positive result from the Acacia readout would validate drugs for non-obstructive hypertrophic cardiomyopathy and suggest that development of iterative drugs like EDG-7500 can progressively drive better benefits, while an Acacia miss could mean a potentially uncontested market, according to the note.

Follow-up data from Edgewise's Cirrus trial also has the potential to drive an about 10% upside, creating a "nice" catalyst path in Q2, while the company's Grand Canyon trial results could be the stock's largest catalyst this year, the brokerage said.

RBC has an outperform, speculative risk rating on the stock, with a $50 price target.

Price: $31.51, Change: $+0.28, Percent Change: +0.90%

Related Articles

Wire

Unico Silver Reduces Rigs at Argentina Drilling Operations During Transition to Winter Operations

Unico Silver (ASX:USL) said it reduced the number of drill rigs under its drilling operations in Argentina to two from three as it moves into reduced winter operations, according to a Friday Australian bourse filing.The company plans to update the Joaquin project mineral resource estimate in the June quarter to incorporate recent infill drilling.In the same filing, the company said it is conducting pre-feasibility work streams, including geotechnical drilling and interpretation to define open-pit slope and design parameters, as well as comminution and metallurgical test work to confirm processing assumptions and recovery pathways.The company's shares fell past 1% in recent trading on Friday.

ASX:USL
Wire

Coursera Q1 Non-GAAP Earnings Fall, Revenue Rises; Shares Drop After Hours

Coursera (COUR) reported Q1 non-GAAP earnings late Thursday of $0.07 per diluted share, down from $0.12 a year earlier.Analysts polled by FactSet expected $0.08.Revenue in the three months ended March 31 rose to $195.7 million from $179.3 million a year earlier.Analysts surveyed by FactSet expected $195.1 million.Coursera expects Q2 revenue of $196 million to $200 million. Analysts project $200.7 million.The company reaffirmed full-year revenue guidance of $805 million to $815 million. Analysts project $812.7 million.Coursera shares fell 10% in after-hours trading.

$COUR
Wire

MaxLinear Q1 Swings to Adjusted Earnings, Revenue Rises; Q2 Guidance Set

MaxLinear (MXL) reported Q1 adjusted earnings late Thursday of $0.22 per diluted share, swinging from a loss of $0.05 a year earlier.Analysts polled by FactSet expected EPS of $0.18.Revenue for the three months ended March 31 was $137.2 million, up from $95.9 million a year earlier.Analysts surveyed by FactSet expected $134.6 million.For Q2, the company expects revenue of $160 million to $170 million. Analysts expect $137.1 million.The company also amended its credit agreement with certain lenders to extend the maturity of the revolving credit facility to March 2028 and also increased the amount available under the facility to $130 million.

$MXL